{
  "docId": "019de075-c1ce-7016-922a-ee59c26b52e2",
  "docSlug": "7a9033616f2f52a3ff84a89721dd4a41",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 23,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c1ce-7016-922a-ee59c26b52e2/10",
  "deckHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2",
  "deckJsonHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2.json",
  "deckAnchorHref": "/decks/019de075-c1ce-7016-922a-ee59c26b52e2#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.21,
        "x": 0.64,
        "y": 0.57
      },
      "kind": "chart",
      "text": "Tumor volume over time (Vehicle vs NXP800)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11883ea6-1b17-4968-8531-af9bb8165435",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.62,
        "y": 0.24
      },
      "kind": "diagram",
      "text": "PDX study workflow: Patient resection -> Implantation -> Treatment initiation -> Euthanasia",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2032f9db-3ca6-4431-bc52-2065c344c7e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.1,
        "x": 0.87,
        "y": 0.57
      },
      "kind": "image",
      "text": "Tumor size comparison (Vehicle vs NXP800)",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dc4edab-adab-46af-ac6d-2556aafa8371",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.21,
        "x": 0.37,
        "y": 0.24
      },
      "kind": "image",
      "text": "MRI scan of liver tumor",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "730c7281-f844-4c02-9db8-f98aa1f1ec73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "list",
      "text": "Cholangiocarcinoma (CCA) is a lethal malignancy with poor prognosis arising from the biliary tree. Approx. 10,000 new cases/year in the US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d1eff3b-e062-46d6-bb80-908ec0e94275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "source-note",
      "text": "a. The cholangiocarcinoma foundation, cholangiocarcinoma.org/key-statistics",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0b693ac-4789-4600-b14f-426cf6673874",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Substantial Antitumor Activity in Cholangiocarcinoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1780bd0c-4be8-4736-b440-7bf35cde2b82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Additional potential development opportunities",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "940753d3-c169-4422-b18d-c5d41ed1b076",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "c1062702-11f0-40ee-8dcf-e049e6911d1a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents Nuvectis Pharma's solution, including NXP800 and NXP900",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 11,
      "from": 9,
      "beatId": "2f58055b-6bfe-4c16-99cc-32b143b3c05f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document presents data on the traction of NXP800 and NXP900",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e81cf698-f51d-4b2d-9877-cb9fc692efbb",
      "evidence": "The document presents the potential benefits of Nuvectis Pharma's pipeline",
      "position": 0,
      "objective": "Highlight the cost of inaction in oncology",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "e770d6a7-7a71-413e-a8f8-c45403042dac",
      "evidence": "The document presents data on the potential of NXP800 and NXP900",
      "position": 1,
      "objective": "Present Nuvectis Pharma's solution as a quick win and big bet",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}